Treatment of venous thromboembolic disease

References

• Engelberg H. Heparin: physiology and pathobiology. Pathobiol Annu 1978: 8: 85–104
   PubMedGoogle Scholar
• Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975: 292(3): 146–51
   PubMed Web of Science ®Google Scholar
• Yin ET, Wessler S, Stoll PJ. Biological properties of the naturally occurring plasma Inhibitor to activated factor X. J Biol Chem 1971: 246(11): 3703–11
   PubMed Web of Science ®Google Scholar
• Hemker HC, Muller AD. Kinetic aspects of the interaction of blood-clotting enzymes. VI. Localization of the site of blood-coagulation inhibition by the protein induced by vitamin K absence (PIVKA). Thromb Diath Haemorrh 1968: 20(Nov 15): 78–87
   PubMedGoogle Scholar
• Coon WW. Anticoagulant treatment of venous thromboembolism. Surg Annu 1972: 4: 151–63
   PubMedGoogle Scholar
• Coon WW, Willis PW 3d. Recurrence of venous thromboembolism. Surgery 1973: 73(6): 823–7
   PubMed Web of Science ®Google Scholar
• O'Sulllvan EF, Hirsh J, McCarthy RA, et al. Heparin in the treatment of venous thrombo-embolic disease: administration, control and results. Med J Aust 1968: 2(4): 153–9
   PubMedGoogle Scholar
• Basu D, Gallus A, Hirsh J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972;287(7): 324–7
   PubMed Web of Science ®Google Scholar
• The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 1973: 47(Suppl II): 1–108
   Google Scholar
• Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982: 307(27): 1676–81
   PubMed Web of Science ®Google Scholar
• Coon WW, Willis PW 3d, Symons MJ. Assessment of anticoagulant treatment of venous thromboembolism. Ann Surg 1959: 170(4): 559–68
   Web of Science ®Google Scholar
• Coon WW, Willis PW 3d. Recurrence of venous thromboembolism. Surgery 1973: 73(Jun): 823–7
   PubMed Web of Science ®Google Scholar
• Hansten PD. Drug interactions. 5th ed. Philadelphia: Lea & Febiger. 1985: 66–114
   Google Scholar
• Glazier RL, Crowell EB. Randomized prospective trial of continuous vs intermittent heparin therapy. JAMA 1976: 236(12): 1365–7
   PubMed Web of Science ®Google Scholar
• Salzman EW, Deykin D, Shapiro RM, et al. Management of heparin therapy: controlled prospective trial. N Engl J Med 1975: 292(20): 1046–50
   PubMed Web of Science ®Google Scholar
• Zucker MB. Heparin and platelet function. Fed Proc 1977: 36(1): 47–9
   PubMedGoogle Scholar
• Zucker MB. Effect of heparin on platelet function. Thromb Diath Haemorrh 1974: 33(1): 63–5
   Google Scholar
• Bell WR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med 1980: 303(16): 902–7
   PubMed Web of Science ®Google Scholar
• Gollub S, Ulin AW. Heparin-induced thrombocytopenia in man. J Lab Clin Med 1962: 59(3): 430–5
   PubMed Web of Science ®Google Scholar
• Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin: a prospective study in 52 patients. Ann Intern Med 1976: 85(2): 155–60
   PubMed Web of Science ®Google Scholar
• Griffith GC, Nichols G Jr, Asher JD, et al. Heparin osteoporosis JAMA 1965: 193(2): 91–4
   Google Scholar
• Jaffe MD, Willis PW 3d. Multiple fractures associated with long-term sodium heparin therapy. JAMA 1965: 193(2): 158–60
   PubMed Web of Science ®Google Scholar
• Thrombolytic therapy in treatment: summary of an NIH consensus conference. Br Med J 1980: 280(6231): 1585–7
   PubMedGoogle Scholar
• Tillet WS, Garner RL. The fibrinolytic activity of hemolytic streptococci. J Exp Med 1933: 58(10): 485–502
   PubMedGoogle Scholar
• MacFarlane RG, Pilling J. Observations on fibrinolysis: plasminogen, plasmin and antiplasmin content of human blood. Lancet 1946: 2(6425): 562–5
   PubMedGoogle Scholar
• Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli. Nature 1983: 301(5897): 214–21
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bergmann SR, Fox KAA, et al. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation 1984: 69(3): 605–10
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Ludbrook PA, Bergmann SR, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984: 310(10): 609–13
   PubMed Web of Science ®Google Scholar
• Verstraete M, Bernard R, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985: 1(8433): 842–7
   PubMed Web of Science ®Google Scholar
• Theiss W, Wirtzfeld A, Fink U, et al. The success rate of fibrinolytic therapy in fresh and old thrombosis of the iliac and femoral veins. Angiology 1983: 34(1): 61–9
   PubMed Web of Science ®Google Scholar
• Sautter RD, Emanuel DA, Fletcher FW, et al. Urokinase for the treatment of acute pulmonary thromboembolism. JAMA 1967: 202(3): 215–8
   PubMed Web of Science ®Google Scholar
• Sasahara AA, Cannilla JE, Belko JS, et al. Urokinase therapy in clinical pulmonary embolism: a new thrombolytic agent. N Engl J Med 1967: 277(22): 1168–73
   PubMed Web of Science ®Google Scholar
• Tow DE, Wagner HN Jr, Holmes RA. Urokinase in pulmonary embolism. N Engl J Med 1967: 277(22): 1161–7
   PubMed Web of Science ®Google Scholar
• Urokinase Pulmonary Embolism Trial Study Group. Urokinase Pulmonary Embolism Trial (phase 1 results): a cooperative study. JAMA 1970: 214(12): 2163–72
   PubMed Web of Science ®Google Scholar
• Urokinase Pulmonary Embolism Trial Study Group. Urokinase-streptokinase embolism trial (phase 2 results): a cooperative study. JAMA 1974: 229(12): 1606–13
   PubMed Web of Science ®Google Scholar
• Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303(15): 842–5
   PubMed Web of Science ®Google Scholar
• Sasahara AA, Shanna GVRK, Tow TE, et al. Clinical use of thrombolytic agents in venous thromboembolism. Arch Intern Med 1982;142(4): 684–8
   PubMedGoogle Scholar
• Bounameaux H, Vermylen J, Collen D. Thrombolytic treatment with recombinant tissue-type plasminogen activator in a patient with massive pulmonary embolism. Ann Intern Med 1985: 103(1): 64–5
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Planc C, Howe CT, et al. Treatment of deep vein thrombosis: a trial of heparin, streptokinase, and arvin. Br Med J 1969: 1(5647): 806–10
   PubMedGoogle Scholar
• Kakkar VV, Howe CT, Laws JW, et al. Late results of treatment of deep vein thrombosis. Br Med J 1969; 1(5647): 810–1
   PubMedGoogle Scholar
• Rösch J, Dotter CT, Seaman AJ, et al. Healing of deep venous thrombosis: venographic findings in a randomized study comparing streptokinase and heparin. AJR 1976: 127(4): 553–8
   PubMed Web of Science ®Google Scholar
• Johansson E, Ericson K, Zetterquist S. Streptokinase treatment of deep venous thrombosis of the lower extremity: clinical, phlebographic and plethysmographic evaluation of early and late results. Acta Med Scand 1976: 199(1–2): 89–94
   PubMedGoogle Scholar
• Elliot MS, Immelman EJ, Jeffery P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979: 66(12): 838–43
   PubMed Web of Science ®Google Scholar
• Watz R, Savidge GF. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis: a comparative study between streptokinase and heparin therapy. Acta Med Scand 1979;205(4): 293–8
   PubMedGoogle Scholar
• Arnesen H, Holseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study. Acta Med Scand 1982: 211(1–2): 65–8
   PubMedGoogle Scholar
• Widmer LK, Brandenberry E, Widner MT, et al. Late sequelae of deep venous thrombosis: follow up of 278 patients after anticoagulation and thrombolytic treatment. Int Angiol 1982: 1: 31–7
   Google Scholar
• Weimar W, Stibbe J, Van Seyen AJ, et al. Specific lysis of an iliofemoral thrombus by administration of extrinsic (tissue-type) plasminogen activator. Lancet 1981: 2(8254): 1018–20
   PubMed Web of Science ®Google Scholar
• Sharma GVRK, Cella G, Parisi AF, et al. Thrombolytic therapy. N Engl J Med 1982: 306(21): 1268–76
   PubMed Web of Science ®Google Scholar